lisocabtagene maraleucel
During a call to discuss its Q2 financial performance, BMS executives discussed plans to make up for the firm's top-selling cancer drug, Opdivo, losing exclusivity by the end of the decade.
Bristol Myers Squibb's Breyanzi Nets Second-Line Lymphoma Approval in Europe
The European Commission approved the autologous CAR T-cell therapy for relapsed lymphoma patients following first-line chemo-immunotherapy.
BMS to Discuss Positive Breyanzi Data in Additional Lymphoma Indications With Health Authorities
Patients with follicular lymphoma and mantle cell lymphoma in the TRANSCEND FL and TRANSCEND NHL 001 trials had high complete response rates on the CAR T-cell therapy.
Opdivo sales increased 15 percent while revenue from cell therapies Breyanzi and Abecma also grew due to increased manufacturing capacity.
EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment
If approved in Europe, Breyanzi would compete with Gilead Sciences' CAR T-cell therapy Yescarta, which netted second-line LBCL approval in Europe last fall.